Nanobodies Market - Global Industry Size, Share, Trends, Opportunity and Forecast, By Type (Mono-Specific, Multi-Specific) By Application (Acquired Thrombotic Thrombocytopenic Purpura (TTP), Respiratory Syncytial Virus Infection, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Oncology, Psoriasis, Chronic Kidney Diseases, Bone Disorders, Others) By End User (Pharmaceutical & Biotechnology Companies, Research Laboratories, and Others), By Region, By Competition, 2020-2030F

Market Overview

The Global Nanobodies Market, valued at USD 578.40 Million in 2024, is projected to experience a CAGR of 18.30% to reach USD 1585.39 Million by 2030. Nanobodies, also known as single-domain antibodies, are compact antibody fragments derived from camelids, characterized by their small size, inherent stability, and high antigen affinity. These properties make them valuable for therapeutic, diagnostic, and research applications. Key growth drivers include rising demand for targeted therapeutics with reduced off-target effects in areas such as oncology and autoimmune conditions, offering superior tissue penetration and lower immunogenicity than traditional antibodies. Expanded utility in diagnostic imaging and biotechnology advancements also propel market expansion.

Supporting this innovation, according to the European Federation of Pharmaceutical Industries and Associations, in 2023, the pharmaceutical industry invested an estimated €50 billion in research and development in Europe. Despite this, a significant challenge impeding market expansion is the high cost associated with nanobody development and large-scale production, necessitating complex biotechnological processes and specialized resources.

Key Market Drivers

The unique physicochemical properties of nanobodies constitute a primary driver for market expansion, owing to their compact size, inherent stability, and exceptional antigen-binding affinity. These attributes facilitate superior tissue penetration and the targeting of cryptic epitopes, often inaccessible to larger conventional antibodies, thus broadening their therapeutic utility. Nanobodies also exhibit lower immunogenicity, reducing the risk of adverse immune responses. The substantial potential of these characteristics attracts significant investment into companies leveraging nanobody platforms. For example, according to Longevity. Technology, in June 2023, Attovia Therapeutics launched with a $60 million Series A financing to advance its proprietary biparatopic nanobody platform, underscoring commercial interest in these inherent advantages. This differentiation positions nanobodies as a preferred modality for addressing complex biological targets.

A second critical factor is the rising demand for targeted therapeutics, especially in oncology and autoimmune diseases, where precision and minimal off-target effects are paramount. Nanobodies, with their high specificity and targeted delivery potential, offer a compelling alternative to traditional treatments, enhancing efficacy and patient safety. Pharmaceutical industry leaders are channeling substantial resources into this area. According to Pharmaceutical Technology, in May 2024, Merck & Co's R&D investments reached $30.5 billion in 2023, with a portion dedicated to strategic partnerships for new cancer targets and antibody-drug conjugates, illustrating this commitment. This strategic shift towards precision medicine fuels novel nanobody drug development. Overall, according to research published in Nature Reviews Drug Discovery, over 150 VHH-based therapeutics are currently in preclinical or clinical development globally, reflecting robust activity in the nanobody sector.

Download Free Sample Report

Key Market Challenges

The high cost associated with nanobody development and large-scale production presents a significant impediment to the global nanobodies market expansion. These substantial expenses arise from the intricate biotechnological processes and specialized resources required throughout the discovery, development, and manufacturing phases. Such financial demands can limit the number of new nanobody therapeutics and diagnostics that can progress from research to commercialization, thus restricting overall market growth.

Developing novel biological entities, including nanobodies, is an inherently capital-intensive endeavor. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the estimated cost for researching and developing a new biological entity reached €3,130 million in 2022. This considerable investment per product candidate means that companies must carefully prioritize projects, often leading to fewer nanobody therapies advancing through the pipeline. The need for advanced purification, quality control, and specialized infrastructure further exacerbates production costs, making it challenging for market players, particularly smaller enterprises, to compete and scale operations effectively. This directly curtails the widespread availability and adoption of nanobody-based products.

Key Market Trends

Advancements in nanobody production and bioprocessing technologies are significantly influencing the global market by enhancing scalability and reducing manufacturing complexities. The Parenteral Drug Association (PDA), at its 2024 Pharmaceutical Manufacturing & Quality Conference, extensively discussed the adoption of multiple advanced techniques, including flexible manufacturing, continuous manufacturing, and process analytical technology, to optimize bioprocessing efficiency. This focus underscores the industry's drive to streamline production and improve quality control. A specific illustration of this progress is a study presented at Regeneron ISEF 2025, where advanced computational methods, utilizing ensemble-stacking techniques, accurately predicted 50 effective nanobody sequences against an antigen target with an R^2 of 0.75, accelerating the discovery and optimization phases. Such innovations contribute to faster development timelines and potentially lower costs for bringing nanobody products to market.

The increased regulatory approvals and subsequent market validation are crucial for building confidence and expanding the reach of nanobody-based therapeutics and diagnostics. This trend is demonstrated by the growing number of nanobody products successfully navigating rigorous regulatory pathways. According to the Biotechnology Innovation Organization (BIO)'s 2024 Special 301 Submission, approximately 500 unique COVID-19 antivirals and treatments were in development globally, showcasing the vast pipeline of biopharmaceutical innovation that relies on robust regulatory support for commercialization. Further evidence of validation comes from a Biopharma PEG review published in October 2023, which noted that four nanobody-based therapies have received worldwide approvals, including Ciltacabtagene autoleucel (cilta-cel), which gained FDA approval in February 2022 for relapsed/refractory multiple myeloma, highlighting successful market entry and clinical acceptance.

Segmental Insights

The Oncology segment is a key driver of growth in the Global Nanobodies Market due to the increasing prevalence of various cancer types and the rising demand for precision medicine approaches. Nanobodies offer distinct advantages in cancer therapy, including high target specificity and enhanced tissue penetration, which enable more effective delivery of therapeutic agents to tumor sites while minimizing off-target effects. Their versatile application extends to targeted drug delivery, immunotherapy, and advanced diagnostic imaging, leading to improved outcomes for patients. Ongoing research and development efforts, coupled with successful clinical trials and recent regulatory approvals for nanobody-based cancer treatments, further underscore this rapid expansion.

Regional Insights

North America leads the global nanobodies market, primarily driven by its mature biotechnology and pharmaceutical industry, which hosts a significant concentration of specialized research institutions and prominent companies. The region benefits from substantial investments in research and development, fostering innovation in nanobody-based therapeutics and diagnostics. A favorable regulatory environment, notably shaped by the U. S. Food and Drug Administration, provides clear pathways and stringent evaluation for biologic drug approvals, thereby facilitating accelerated development and commercialization. Furthermore, high awareness and early adoption of nanobody technology within well-developed healthcare systems contribute significantly to its market dominance.

Recent Developments

• In October 2025, Radiance Biopharma announced an exclusive licensing agreement with Novatim Immune Therapeutics for the development and commercialization of RB-601 (KY-0301). This bispecific nanobody antibody-drug conjugate (ADC) was designed to simultaneously target both c-MET and EGFR, aiming to treat various solid tumors. Under the terms, Radiance Biopharma made an upfront payment of $15 million and agreed to potential development and regulatory milestones up to $150 million, in addition to over $1 billion in commercial milestones and tiered royalties. Radiance secured global rights, excluding certain Asian markets, and assumed responsibility for clinical development in its licensed territories.

• In February 2025, Grifols, a global healthcare company, entered into a strategic collaboration with Fcr Therapeutics BV. This partnership was established with the goal of developing recombinant nanobodies specifically engineered to target and address autoimmune diseases. The agreement underscored a shared commitment to harnessing the distinctive characteristics of nanobodies, such as their small size, enhanced stability, and specific binding capabilities, to create innovative therapeutic solutions. This joint effort aimed to advance the research and development pipeline, ultimately providing novel treatment options for individuals affected by various autoimmune disorders.

• In June 2024, Shaperon, a biopharmaceutical company specializing in immune therapeutics, and Dong-A ST, a pharmaceutical company, formalized a Memorandum of Understanding. This collaboration focused on the development of new nanobody-based drugs, particularly triple nanobody antibodies for cancer treatment. The partnership aimed to integrate Shaperon's nanobody development platform with Dong-A ST's expertise in antibody commercialization. The objective was to accelerate the discovery and potential market entry of these novel nanobody therapeutics, leveraging the inherent high stability and solubility of nanobodies for advanced immune checkpoint inhibitors.

• In March 2024, MoonLake Immunotherapeutics, a clinical-stage biotechnology company, reported positive 24-week data from its Phase 2 ARGO trial. The study evaluated sonelokimab, an investigational nanobody designed to inhibit IL-17A and IL-17F, which are key drivers of inflammation. The results demonstrated significant improvements across all primary outcomes in patients with active psoriatic arthritis (PsA). Sonelokimab, a humanized nanobody comprising three VHH domains, displayed its potential as a therapeutic candidate for inflammatory diseases by selectively binding to inflammatory cytokines and concentrating at sites of inflammation.

Key Market Players

• Hybrigenics Services
• Novo Nordisk A/S
• Merck KGaA
• Bristol Myers Squibb Company
• Boehringer Ingelheim International GmbH
• Sanofi S.A
• Beroni Group
• Shenzhen Kangti Co., Ltd.
• GlaxoSmithKline plc
• Sensei Biotherapeutics, Inc

Report Scope:

In this report, the Global Nanobodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Nanobodies Market, By Type:

o   Mono-Specific

o   Multi-Specific

• Nanobodies Market, By Application:

o   Acquired Thrombotic Thrombocytopenic Purpura (TTP)

o   Respiratory Syncytial Virus Infection

o   Rheumatoid Arthritis

o   Systemic Lupus Erythematosus

o   Oncology

o   Psoriasis

o   Chronic Kidney Diseases

o   Bone Disorders

o   Others

• Nanobodies Market, By End User:

o   Pharmaceutical & Biotechnology Companies

o   Research Laboratories

o   Others

• Nanobodies Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Nanobodies Market.

Available Customizations:

Global Nanobodies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Nanobodies Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]